Obesity trials recruiting in Georgia

All Obesity trials nationally

Cities in Georgia

Recruiting trials in Georgia

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Union City
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Columbus, Union City
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Woodstock
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Conyers, Decatur
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female) · Georgia: Atlanta, Columbus, Decatur, Snellville
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Conyers, Gainesville, Roswell, Woodstock
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Acworth, Atlanta, Conyers, Gainesville
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Georgia: Atlanta, Columbus, Lawrenceville, Union City
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Dunwoody, Lawrenceville, Macon
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Dunwoody, Lawrenceville, Stockbridge
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Lawrenceville, Snellville
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Dunwoody, Gainesville, Stockbridge
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Lawrenceville, Union City, Woodstock
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
  NCT07215559 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Atlanta, Lawrenceville, Sandy Springs, Stonecrest
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Canton, Decatur, Union City
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Canton, Decatur, Union City
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
  NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Decatur, Woodstock
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · Georgia: Lawrenceville
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Stockbridge
• A Study of Pitolisant in Patients With Prader-Willi Syndrome
  NCT06366464 · Phase: Phase 3 · Ages: 6 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
  NCT07724340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Decatur, Savannah
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Stockbridge
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Marietta, Waycross
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Douglasville
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Georgia: Gainesville, Lawrenceville
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Fayetteville
• AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
  NCT07339423 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Conyers
• AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571005 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Lawrenceville
• AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Lawrenceville
• Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss)
  NCT06420700 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
  NCT05082519 · Phase: Phase 2 · Ages: 7 Years to 25 Years · Sex: All (male and female) · Georgia: Atlanta
• Cottonseed Oil Versus Matched PUFA Effects
  NCT06382298 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 75 Years · Sex: All (male and female) · Georgia: Athens
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Georgia: Buford, Columbus, Lawrenceville, Union City
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Decatur
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Decatur
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Albany
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Decatur, Lilburn, Marietta, Riverdale
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Lilburn
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Georgia: Johns Creek, Union City, Woodstock
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Georgia: Canton, Macon, Savannah
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Georgia: Gainesville, Union City
• Intermittent Cottonseed Oil Consumption
  NCT07246408 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 75 Years · Sex: All (male and female) · Georgia: Athens
• Lifestyle Intervention for Healthy Change
  NCT05956574 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 40 Years · Sex: All (male and female) · Georgia: Augusta
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
  NCT07226765 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Georgia: Atlanta
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
  NCT07225686 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Georgia: Atlanta
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Georgia: Atlanta, Peachtree City
• Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults
  NCT07221279 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years and older · Sex: All (male and female) · Georgia: Kennesaw
• Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
  NCT07446998 · Phase: Phase 2 · Ages: 65 Years to 100 Years · Sex: All (male and female) · Georgia: Atlanta
• Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
  NCT06585462 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Georgia: Union City
• Sisters for Heart Health: A Community Health Worker Initiative for Improving Heart Health in Farmworker Women
  NCT07111026 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: Female · Georgia: Ellenton